3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
5
Not yet recruiting
3
Suspended
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Specimen Handling
116
Magnetic Resonance Spectroscopy
94
Biopsy
60
pembrolizumab
58
Carboplatin
57
Cisplatin
51
Nivolumab
47
Cyclophosphamide
40
Radiotherapy
39
Paclitaxel
37
Gemcitabine
34
Dexamethasone
34
Bevacizumab
31
Radiation
30
atezolizumab
29
Pemetrexed
28
venetoclax
25
olaparib
25
Etoposide
25
X-Rays
24
Prednisone
23
Immunoglobulin G
23
Doxorubicin
23
Disulfides
23
Vincristine
22
Lenalidomide
22
Leucovorin
21
Ipilimumab
21
durvalumab
20
Taxes
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled